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17 Abstract—Sensorineural hearing losses (SNHLs; e.g.,
ototoxicant- and noise-induced hearing loss or presbycusis)
are among the most frequent sensory deﬁcits, but they lack
eﬀective drug therapies. The majority of recent therapeutic
approaches focusedon the trials of antioxidants and reactive
oxygen species (ROS) scavengers in SNHLs. The rationale
for these studies was the prominent role of disturbed redox
homeostasis and the consequent ROS elevation. Although
the antioxidant therapies in several animal studies seemed
to be promising, clinical trials have failed to fulﬁll expecta-
tions. We investigated the potential of rasagiline, an
FDA-approved monoamine oxidase inhibitor type B
(MAO-B) inhibitor type anti-parkinsonian drug, as an otopro-
tectant. We showed a dose-dependent alleviation of the
kanamycin-induced threshold shifts measured by auditory
brainstem response (ABR) in an ototoxicant aminoglycoside
antibiotic-based hearing loss model in mice. This eﬀect
proved to be statistically signiﬁcant at a 6-mg/kg (s.c.) dose.
The most prominent eﬀect appeared at 16 kHz, which is the
hearing sensitivity optimum for mice. The neuroprotective,
antiapoptotic and antioxidant eﬀects of rasagiline in animal
models, all targeting a speciﬁc mechanism of aminoglyco-
side injury, may explain this otoprotection. The dopaminer-
gic neurotransmission enhancer eﬀect of rasagiline might
also contribute to the protection. Dopamine (DA), released
from lateral olivocochlear (LOC) ﬁbers, was shown to exert
a protective action against excitotoxicity, a pathological
factor in the aminoglycoside-induced SNHL. We have shown
that rasagiline enhanced the electric stimulation-evoked
release of DA from an acute mouse cochlea preparation in
a dose-dependent manner. Using inhibitors of voltage-gated
Na+-, Ca2+ channels and DA transporters, we revealed that
rasagiline potentiated the action potential-evoked release
of DA by inhibiting the reuptake. The complex, multifacto-
rial pathomechanism of SNHLs most likely requires drugs
acting on multiple targets for eﬀective therapy. Rasagiline,
with its multi-target action and favorable adverse eﬀects
proﬁle, might be a good candidate for a clinical trial testing
the otoprotective indication.  2014 Published by Elsevier
Ltd. on behalf of IBRO.
Key words: sensorineural hearing loss, kanamycin, auditory
brainstem response, lateral olivocochlear efferents, dopa-
mine, rasagiline.
18
19INTRODUCTION
20SNHLs and the lack of their eﬀective pharmacological
21treatment
22Hearing loss (HL) is the most frequent human sensory
23deﬁcit. In contrast to its conductive forms, there is no
24speciﬁc drug therapy for sensorineural hearing losses
25(SNHLs; e.g., ototoxicant drug- and noise-induced HL or
26presbycusis), except for symptomatic approaches with
27moderate eﬃcacy. One of the main reasons for the
28absence of speciﬁc tools to prevent and cure SNHLs is
29the insuﬃcient knowledge of the basic molecular
30mechanisms of normal and impaired adult hearing and
31of the endogenous protective factors.
32A consensus is evolving that the imbalance of the
33redox homeostasis and the consequent increase in
34reactive oxygen and nitrogen species (ROS, RNS) is a
35common pathological basis in all the acquired forms of
36SNHLs (Mukherjea et al., 2011), as well as in the many
37inherited forms (Noben-Trauth and Johnson, 2009). This
38knowledge initiated testing of diﬀerent antioxidants and
39ROS scavengers (Tabuchi et al., 2010; Mukherjea et al.,
402011) for the protection of the cells of the organ of Corti
41and auditory neurons, which are primary targets in
42SNHLs.
43Rasagiline
44Rasagiline, a selective propargylamine inhibitor of
45monoamine oxidase inhibitor (MAO) type B, has been
46applied to Parkinson’s disease in clinical practice
47(Finberg, 2010). In addition to selectively inhibiting the
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48 dopamine (DA) metabolizing enzyme MAO-B, it also has
49 a cell protective action. It has been shown to protect
50 against neural degeneration (Huang et al., 1999;
51 Speiser et al., 1999; Youdim et al., 2006), oxidative
52 damage and apoptosis (Tabakman et al., 2004;
53 Siderowf and Stern, 2006). These protective eﬀects
54 provide a rational to test its eﬀect in diﬀerent forms of
55 SNHLs. Furthermore, as an enhancer of DAergic
56 neurotransmission (Weinreb et al., 2010) in the central
57 nervous system, it may also potentiate the release of
58 DA from the lateral olivocochlear (LOC) eﬀerents, which
59 is considered to be a protective feedback pathway of
60 the cochlea (Pujol et al., 1993; Pujol, 1994; Lendvai
61 et al., 2011; Maison et al., 2013).
62 The cochleoprotective role of DA released from LOC
63 eﬀerent ﬁbers
64 It has been shown that the excessive release of glutamate
65 (Glu) from inner hair cells (IHCs) in noise-induced HL,
66 presbycusis, cochlear ischemia or aminoglycoside-
67 induced ototoxicity results in the excitotoxic damage of
68 the primary auditory neurons (Duan et al., 2000; Ruel
69 et al., 2007; Tabuchi et al., 2010; Bernarding et al.,
70 2013). LOC eﬀerents, forming axodendritic synapses with
71 the auditory neurons, serve as the eﬀector arm of the
72 auditory neurons – cochlear nucleus – lateral superior
73 olivary complex – cochlea short-loop feedback and
74 provide protection to the auditory neurons against
75 excitotoxicity by releasing DA. DA inhibits the
76 postsynaptic eﬀects of Glu and protects the IHC-aﬀerent
77 nerve synapse (Halmos et al., 2005, 2008; Ruel et al.,
78 2007; Lendvai et al., 2011). Intracochlear application of
79 the D2/D3 dopamine receptor agonist piribedil reduced
80 the characteristic electrophysiological and structural
81 changes evoked by acoustic trauma and ischemia (Pujol
82 et al., 1993; d’Aldin et al., 1995a,b; Gil-Loyzaga, 1995),
83 and D1, D2 receptor agonists were shown to inhibit the
84 NMDA- and AMPA-induced ﬁring of the primary aﬀerent
85 nerve (Oestreicher et al., 1997). Although drugs acting on
86 the DAergic system have not yet been tested thoroughly,
87 theoretically, any drug able to boost the function of this
88 system could hold preventive or curative promises for
89 SNHLs (Halmos et al., 2005; Lendvai et al., 2011).
90 Aminoglycoside ototoxicity and its use as a SNHL
91 model
92 Aminoglycoside antibiotics, which still need to be used in
93 the treatment of certain serious infections caused by
94 aerobic gram-negative bacteria, can induce irreversible
95 HL (Xie et al., 2011). Hair cells, especially the outer hair
96 cells and the IHC ribbon synapse, together with the
97 auditory neurons, are very vulnerable to the
98 administration of aminoglycosides (Ylikoski et al., 1974;
99 Dodson, 1997; Duan et al., 2000; Maruyama et al.,
100 2008; Fransson et al., 2010; Liu et al., 2013). The
101 pivotal role of normal redox state disturbances,
102 generation of ROS and excitotoxic damage of the
103 auditory neurons in the pathomechanism has been
104 shown in several studies (Basile et al., 1996; Sha and
105 Schacht, 1999; Duan et al., 2000; Poirrier et al., 2010;
106Huth et al., 2011). This serious side eﬀect is the basis
107of a well-established animal model used in hearing
108research (Wu et al., 2001). As the aminoglycoside
109induced HL involves oxidative stress, ROS generation
110and excitotoxic neuronal damage, we tested the eﬀect
111of rasagiline in the kanamycin-induced hearing loss
112model.
113EXPERIMENTAL PROCEDURES
114In vivo measurement of the rasagiline eﬀect in the
115aminoglycoside-induced ototoxicity model
116General experimental paradigm of kanamycin-induced
117ototoxicity and application of rasagiline. All animal care
118and experimental procedures were in accordance with
119the National Institute of Health Guide for the Care and
120Use of Laboratory Animals. Procedures were approved
121by the Animal Use Committee of the Institute of
122Experimental Medicine, Hungarian Academy of
123Sciences. Selections of the mouse strain and the type
124and concentration of aminoglycoside antibiotic were
125based on data from the literature (Wu et al., 2001). Our
126preliminary experiments (data not shown) testing
127diﬀerent mouse strains, aminoglycoside antibiotics and
128concentrations of kanamycin, conﬁrmed that the most
129pronounced and reliable aminoglycoside-induced
130hearing loss, suitable for testing otoprotection, could be
131produced in BALB/c mice by administering kanamycin in
132an 800 mg/kg s.c. dose. Male BALB/c mice, age
1334 weeks, were purchased from Charles River, Germany.
134First, a set of experiments exploring also the dynamics
135of the eﬀect of kanamycin and rasagiline was carried out.
136Mice were assigned to one of the following four
137experimental groups: (1) Control (physiological saline),
138(2) Kanamycin, 800 mg/kg, (3) Rasagiline, 3 mg/kg, and
139(4) Kanamycin, 800 mg/kg + Rasagiline, 3 mg/kg.
140Treatment groups contained eight mice each. (One
141mouse in group 4 died during the auditory brainstem
142response (ABR) measurement under anesthesia.)
143Kanamycin sulfate (USB Corporation, Cleveland, OH)
144was injected s.c. twice daily (8–9 a.m. and 6–7 p.m.) for
1452 weeks. The ﬁrst dose of the antibiotic was administered
146on the day of the ﬁrst ABR measurement (6–7 p.m.) after
147all the measurements had been performed. Doses of
148rasagiline mesylate (3 mg/kg, s.c.; TEVA) were given
149once daily at the same time as the morning dose of
150kanamycin, but the injections were separate. In this way,
151the ﬁrst dose of rasagiline was delivered 14 h after the
152ﬁrst kanamycin dose. Rasagiline treatments lasted
1535 weeks. Mice in the Control group were injected s.c. by
154an equivalent amount of physiological saline. In the
155kanamycin treatment group, after the 2nd week, the
156kanamycin injections were replaced by injections of
157physiological saline till the end of the 5th week.
158Auditory thresholds were determined in both ears from
159the ABRs. Thresholds were taken from each animal prior
160to the start of the drug treatments on the 1st week (start-
161up threshold), 2 weeks after the start of drug treatment,
162and then weekly up to 5 weeks (5 measurements in
163sum). The threshold shift gives the diﬀerence of an
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164 actual threshold value and the threshold measured in the
165 same mouse before any treatment (start-up threshold).
166 Based on the time-dependent threshold changes
167 measured in the ﬁrst set of experiments, a 3-week-long
168 experiment was performed, and two other doses of
169 rasagiline were tested (1. Control, 2. Kanamycin, 800 mg/kg,
170 3. Kanamycin, 800 mg/kg + Rasagiline, 0.5 mg/kg, 4.
171 Kanamycin, 800 mg/kg + Rasagiline, 6 mg/kg). The ABR
172 was measured in the left ear exclusively. The experiment
173 was carried out with larger sample sizes (n= 20 in each
174 treatment group), which were calculated based on the
175 ﬁrst set of experiments. Two mice in the Control group,
176 one in the kanamycin group and two in the
177 kanamycin + rasagiline, 6 mg/kg treatment group died
178 during the ABR measurement under anesthesia. The
179 kanamycin dose and the treatment protocols were the
180 same as before.
181 In vivo recordings of ABRs. Micewere anesthetized by
182 i.p. injections of ketamine (100 mg/kg) and xylazine
183 (10 mg/kg). Body temperature was maintained by a
184 feedback-controlled heating pad. The auditory thresholds
185 were determined by an ABR workstation (Tucker-Davis
186 Technologies, Alachua, FL). Click (0.4-ms duration) and
187 tone burst (3-ms duration, 0.2-ms rise/decay) stimuli
188 were generated by the SigGen software package and
189 delivered in a closed acoustic system to the external
190 auditory meatus through a plastic tube connected to an
191 EC1 electrostatic speaker. ABRs were recorded with
192 subdermal needle electrodes as the potential diﬀerence
193 between an electrode on the vertex and an electrode
194 behind the left or right pinna. The rear leg served as a
195 ground. The evoked responses were ampliﬁed, and 800
196 sweeps were averaged in real time. The intensity was
197 increased in 10-dB steps from 0 to 80-dB in click
198 stimulation mode. To obtain auditory thresholds at
199 diﬀerent frequencies, the sound intensity of the tone
200 burst stimuli were attenuated in 10-dB steps. Threshold
201 was deﬁned as the lowest intensity at which a visible
202 ABR wave was seen.
203 Statistical analysis. Threshold data in both studies
204 were analyzed using a linear mixed statistical model (to
205 take into account the fact that every animal was
206 measured on each frequency, the ‘‘nlme’’ package of the
207 R statistical program was used (Pinheiro et al., 2013; R
208 Core Team, 2013), followed by pairwise comparisons of
209 the treatments, calculated using contrasts (Warnes,
210 2011). Left and right ear values were averaged in the
211 ﬁrst set of experiments. Model eﬀects were tested
212 together based on their F values. All factors and
213 potential interactions were evaluated with the cut-oﬀ for
214 inclusion of P< 0.05. The Tukey–Kramer corrections of
215 p-values and conﬁdence limits were applied.
216 In vitro measurement of DA release from the LOC
217 terminals
218 Measuring the release of DA from mouse and guinea-
219 pig cochlea. CD-1 male mice, weighing 20–35 g, were
220 used. Procedures were approved by the Animal Use
221Committee of the Institute of Experimental Medicine,
222Hungarian Academy of Sciences. We used the
223microvolume superfusion method as described earlier
224(Ga´borja´n et al., 1999; Halmos et al., 2005, 2008).
225Brieﬂy, the bulla tympani was opened. The bony capsule
226of the cochlea was removed under stereomicroscopic
227guidance, the stria vascularis was stripped, and the
228cochlea was fractured at the basis of the modiolus. Our
229preparation contained the ganglion spirale, the aﬀerent
230auditory ﬁbers, the axons and axon terminals of the
231eﬀerent bundles and both the inner and outer hair cells.
232All experiments were carried out in a perilymph-like
233solution (Ikeda et al., 1991), which contained 150 mM
234NaCl, 3.5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 2.75 mM
235HEPES and 2.25 mM Tris at 37 C. The pH was
236adjusted to 7.4. The osmolarity was set by D-glucose,
237and the solution was gassed continuously with 100% O2.
238The cochleae were incubated with 0.2 lM
239[3H]dopamine (speciﬁc activity: 31.0–59.3 Ci/mmol;
240[7,8-3H]DA, Amersham, UK) for 35 min, placed in a
241microvolume plexi chamber (three cochleae per
242chamber) and then superfused with a perilymph-like
243solution (3 ml/min). After one hour pre-perfusion, the
244outﬂow was collected in 3-min fractions. The released
245radioactivity, indicating the release of DA from the LOC
246terminals, was determined by assaying 500 ll aliquots of
247each sample with a liquid scintillation counter (Packard
248Tri-Carb 1900TR). After collecting the samples for
24957 min (19 fractions), each cochlea was transferred from
250the microchambers to 500 ll of 10% trichloroacetic acid
251for one day; 100 ll was then used to measure the tissue
252content of the radioactivity. Earlier HPLC measurements
253in our laboratory showed that 91–95% of the released
254radioactivity was attributable to [3H]DA and its
255metabolites DOPAC and HVA (Ga´borja´n and Vizi, 1999).
256Electrical ﬁeld stimulation, evoking action potentials in
257the LOC eﬀerents, was applied for one collection period
258(3 min) at 30-V, 5-Hz and 0.5-ms impulse duration at
259the 3rd (S1) and 13th (S2) fractions. The pulses were
260delivered by a Grass S88 stimulator (West Warwick,
261USA) through platinum electrodes at the top and bottom
262of the tissue chamber. Rasagiline was added to the
263perfusion solution at the beginning of the 8th fraction
264(21th min) and was maintained till the end of the
265experiment. Perfusion of CdCl2 and TTX was started
2666 min earlier (from the 15th min). The application of
267nomifensine and a decrease in the temperature to 17 C
268were started in the 45th min of pre-perfusion and were
269maintained till the end of the experiment.
270In addition to the reversibility and reproducibility of DA
271release and its inhibition by voltage-gated sodium
272(VGSC) or voltage-gated calcium channel (VGCC)
273blockade (indications of neuronal exocytosis; see
274Ga´borja´n and Vizi, 1999; Ga´borja´n et al., 1999; Halmos
275et al., 2008), the viability of the cochlear preparation was
276also shown by light- and electron microscopy (EM)
277performed immediately before and after the experiments
278(Halmos et al., 2008).
279Data analysis and statistics. To best describe the
280release of DA during one collecting period, the fractional
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281 release (FR) of the tritium outﬂow was determined as the
282 percentage of the total radioactivity present in the tissue
283 at the time of sample collection. The FR due to the ﬁeld
284 stimulations (S1 and S2) was calculated by the area-
285 under-the-curve, i.e., by subtracting the mean of the
286 basal release, determined from FR values before and
287 after the stimulation, from the total FR during the
288 electrical stimulation (Halmos et al., 2000, 2005). The
289 eﬀects of drugs on the ﬁeld stimulation-evoked [3H]DA
290 release were expressed by the calculated ratio of FR S2
291 over FR S1 (FRS2/FRS1). Data are expressed as the
292 means ± SEM. Analysis of variance (ANOVA) followed
293 by Tukey’s Honest Signiﬁcant Diﬀerence method for
294 multiple comparisons was used to compare the
295 treatment groups with the R 14.1 program. Levels of
296 signiﬁcance were as follows: ⁄p< 0.05, ⁄⁄p< 0.01 and
297
⁄⁄⁄p< 0.001.
298 RESULTS
299 In vivo eﬀect of rasagiline on aminoglycoside-
300 induced hearing impairment
301 The eﬀect of rasagiline on SNHL was tested in the
302 kanamycin-induced hearing loss model in mice (Wu
303 et al., 2001). Auditory thresholds were measured at four
304 diﬀerent frequencies.
305 First, a ﬁve-week-long study was started with eight
306 mice in each treatment group (Fig. 1) to explore the
307 time dependency of the threshold changes. Kanamycin
308 (800 mg/kg, s.c.), administered for 2 weeks twice daily
309 impaired the hearing of BALB/c mice. The shift of the
310 auditory thresholds was highly signiﬁcant (p< 0.001) at
311 higher frequencies (16 and 24 kHz), while the ototoxic
312 eﬀect was less pronounced at lower frequencies (not
313 even signiﬁcant at 8 kHz, see the legend of Fig. 1). After
314 3 weeks, a plateau in impairment was reached (Fig. 1).
315 Administration of rasagiline showed a clear tendency of
316 attenuation of the kanamycin-induced threshold
317 elevation. This is clearly seen at all four frequencies at
318 any time point measured, although the diﬀerence was
319 not statistically signiﬁcant (Fig. 1). Contrary, the trace of
320 rasagiline administration alone (3 mg/kg) was
321 sometimes below, sometimes above the control trace
322 (physiological saline) at all four frequencies during the
323 5-week-long experiment. This is in accordance with the
324 lack of signiﬁcant eﬀect of rasagiline on the ‘control’
325 threshold (Fig. 1).
326 The kanamycin-induced hearing loss developed
327 thoroughly up to the 3rd week, and the inﬂuence of
328 rasagiline on kanamycin action did not change during
329 the 5 weeks. Therefore, in a second set of experiments,
330 we tested the eﬀect of rasagiline on threshold shifts in
331 the 3rd week at 0.5 and 6 mg/kg (s.c.) doses.
332 Administration of kanamycin caused a signiﬁcant shift in
333 the auditory thresholds both in click (p< 0.01) and tone
334 burst stimulation modes (4 kHz, p< 0.05; 8 kHz,
335 p< 0.001; 16 kHz, p< 0.001; 24 kHz, p< 0.001). The
336 eﬀect was more robust at the higher frequencies
337 (Fig. 2). Rasagiline mitigated the kanamycin-evoked
338 hearing impairment by 0.5–8 and 8–19 dB when applied
339 in 0.5 and 6 mg/kg dose, respectively. The dose-
340dependency of the rasagiline eﬀect was more prominent
341when its action in 3 mg/kg dose was included in the
342plotting (Fig. 2). The most pronounced protection
343appeared at 16 kHz (Fig. 2).
344We showed in a separate experiment that rasagiline
345alone did not inﬂuence signiﬁcantly the auditory
346thresholds during the 3-week-long treatment even in the
347highest dose (6 mg/kg). The estimated overall diﬀerence
348was 0.24 ± 0.928 dB (p= 0.798, n= 7).
349Eﬀect and mode of action of rasagiline on the release
350of DA from mouse cochlea
351Rasagiline enhanced the electrical ﬁeld stimulation-
352evoked release of DA from isolated mouse cochlea
353preparations (Fig. 3). The eﬀect was concentration-
354dependent and reached a plateau at 100 lM (Fig. 3,
355inset). The resting release of DA was not aﬀected in any
356concentration applied (Fig. 3).
357To explore the possible molecular mechanism of the
358action underlying the eﬀect of rasagiline on the DA
359release evoked by the ﬁeld stimulation, we tested the
360eﬀect of 100 lM rasagiline during the inhibition of
361VGCCs and VGSCs. In the presence of Cd2+ (100 lM)
362and TTX (1 lM), respectively, the stimulation-evoked
363release was completely inhibited, providing evidence
364that the release of DA was due to axonal activity and
365Ca2+ inﬂux. Under these conditions, rasagiline failed to
366increase the release of DA (Fig. 4).
367Blocking the reuptake of DA into the nerve terminals is
368a known way of potentiation of DAergic
369neurotransmission. In order to test whether the uptake
370inhibition is a possible mechanism in rasagiline action
371on cochlear DA release, we measured the eﬀect of
372rasagiline in the presence of uptake inhibition by low
373temperature or nomifensine. Cooling down the
374temperature to 17 C before S2, but after S1,
375approximately doubled the FRS2/FRS1 ratio (2.52 ± 0.4,
376n= 4), conﬁrming its eﬃcacy in inhibition of the uptake,
377similar to what we have shown in brain slices (Vizi,
3781998; Vizi et al., 2004). The inhibitory eﬀect of 10 lM
379nomifensine on mouse cochlear DA reuptake has
380already been demonstrated in our previous work
381(Halmos et al., 2008). During inhibition of DA uptake by
382either nomifensine (10 lM) or low temperature (17 C),
383the potentiating eﬀect of rasagiline was hampered
384signiﬁcantly. These ﬁndings indicate that rasagiline
385inhibits DA uptake in isolated in vitro cochlea
386preparations, thereby potentiating DA’s release from the
387LOC in response to axonal activity (Fig. 5).
388DISCUSSION
389Current therapeutic regimen and potential new drugs
390in SNHLs
391Contrary to the conductive HLs, there are no speciﬁc
392pharmaceuticals for the sensorineural forms in the
393treatment of hearing deﬁcits. Various hearing aids and
394cochlear implants have been proven to be eﬀective
395therapies in appropriate clinical cases; however, a
396speciﬁc drug therapy is still missing. In current clinical
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397 practice, steroids, thrombolytics, vasodilators and
398 nootropic drugs are administered.
399 Potentially new therapeutic approaches in SNHLs
400 based on animal studies, including antioxidants and ROS/
401 RNS scavengers, apoptosis inhibitors, neuroprotective
402 compounds, anti-inﬂammatory drugs (such as steroids,
403 aspirin or TNF-a inhibitors), neurotrophic factors or
404 diﬀerent gene therapeutic approaches (Atar and
405 Avraham, 2005; Rybak and Whitworth, 2005; Maruyama
406 et al., 2008; Fransson et al., 2010; Mukherjea et al., 2011;
407 Rudnicki and Avraham, 2012; Kohrman and Raphael,
408 2013), have been applied, but they have failed to fulﬁl
409 expectations. Although several animal studies have
410 shown signiﬁcant eﬀects of antioxidant therapy, clinical
411 studies have not yet reached a conclusive result (Tabuchi
412 et al., 2010; Mukherjea et al., 2011). Therefore, we
413 considered it relevant to test whether rasagiline, a
414 registered drug with a complex neuroprotective,
415 antiapoptotic and antioxidant eﬀect, possessed any
416 otoprotective action.
417 Testing the potential otoprotective action of
418 rasagiline in vivo in an aminoglycoside-induced form
419 of SNHL
420 Compounds showing a potential to prevent or cure
421 hearing impairments in in vitro experiments need
422reliable in vivo testing to support their applicability in
423therapy. The otoprotective eﬀects of a compound can
424be tested in vivo by measuring its eﬀect on an auditory
425threshold elevated by a pathological insult. The use of
426aminoglycoside antibiotics, which have a well-known
427ototoxic side eﬀect in medical practice, is widely
428accepted for evoking hearing impairment and testing
429potentially otoprotective compounds (Basile et al., 1996;
430Song et al., 1997; Duan et al., 2000; Nekrassov and
431Sitges, 2000; Wu et al., 2001). The mechanism of
432aminoglycosides-induced toxicity involves excitotoxicity
433(Basile et al., 1996; Duan et al., 2000) and the pivotal
434role of oxidative stress and ROS (Basile et al., 1996;
435Sha and Schacht, 1999; Poirrier et al., 2010; Huth et al.,
4362011). To determine the threshold in vivo, the recording
437of the ABR is a method of choice to obtain objective
438audiograms. The mouse is a well-established
439experimental model for human audition as it possesses
440a similar cochlear anatomy, physiology and pattern of
441ototoxicity-related hearing loss (Wu et al., 2001;
442Fernandez et al., 2010).
443Based on the literature (Wu et al., 2001) and
444preliminary experiments, we used 800 mg/kg kanamycin
445(s.c.) for 2 weeks in our aminoglycoside-induced SNHL
446model to test the otoprotective potential of rasagiline
447in vivo. The kanamycin-evoked shift in the auditory
448thresholds was more pronounced at higher frequencies,
Fig. 1. 5-Week-long follow-up of in vivo rasagiline eﬀect in an aminoglycoside-induced SNHL model in mice. Kanamycin (800 mg/kg, s.c., twice
daily) was administered for 2 weeks, and it induced an elevation in hearing thresholds, especially at higher frequencies (compared to Control; p
values were 0.017, 0.066, < 0.001 and <0.001 at 4, 8, 16 and 24 kHz, respectively). Rasagiline treatments (3 mg/kg, s.c., once daily) were started
14 h after the ﬁrst dose of kanamycin, and they lasted 5 weeks. Although rasagiline showed a tendency to decrease the kanamycin-induced
threshold elevation at all measured time points and frequencies, these eﬀects were not statistically signiﬁcant. Mice in the Control group received
physiological saline s.c. twice daily for 5 weeks. The eﬀect of rasagiline alone did not diﬀer from the Control. ABRs were recorded in BALB/c mice at
four frequencies, as described in the Methods. Data are the mean ± SEM; n= 8, except in Kanamycin + Rasagiline (n= 7). A linear mixed
model, followed by pairwise comparisons, was used for the statistical analysis (see Methods).
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449which was in perfect accordance with the observations of
450other studies in both human clinical practice and in
451laboratory animals. Aminoglycoside ototoxicity appears
452as a high-frequency SNHL (Wu et al., 2001; Guthrie,
4532008). Plotting the auditory thresholds as a function of
454time, measured at diﬀerent frequencies, demonstrated
455that the plateau in the eﬀect of kanamycin was reached
456after 3 weeks. This result was in good agreement with
457prior clinical observations that the ototoxic eﬀect of the
458aminoglycosides might start after the cessation of
459treatment, develop slowly and ultimately become
460irreversible (Xie et al., 2011). In our experiments, the
461kanamycin-induced hearing loss had a tendency to be
462attenuated by the concomitant application of a single
463dose per day of rasagiline (3 mg/kg), and this beneﬁcial
464tendency was maintained at multiple frequencies during
465the experiments that lasted for 5 weeks. The eﬀect of
466rasagiline on the auditory thresholds showed dose-
467dependency. The most pronounced eﬀect was exerted
468at 16 kHz. This frequency is right in the range of the
469hearing sensitivity optimum (15–20 kHz) of the mouse
470(Ehret, 1976) and is the equivalent of the human
4711–4 kHz optimum. With these ﬁndings, it is tempting to
472hypothesize that the otoprotection by rasagiline could be
473predominantly exerted in the frequency range most
474relevant to speech acquisition.
475The question arises regarding the potential mechanism
476of the otoprotective action of rasagiline. Rasagiline,
477indicated for the treatment of idiopathic Parkinson’s
478disease by the FDA, possesses neuroprotective,
479anti-apoptotic and antioxidant properties all in one. It
480upregulates the synthesis of anti-apoptotic members of
481the Bcl-2 family and of the neurotrophic factors BDNF
Fig. 2. Rasagiline attenuated the kanamycin-induced hearing impair-
ment in BALB/c mice. ABRs were recorded right before drug
administration (start-up threshold) and 3 weeks later as described in
the Methods. Threshold shifts were calculated as the diﬀerence
between the two measurements. Kanamycin (800 mg/kg, s.c., twice
daily) was administered for 2 weeks, and it induced a signiﬁcant loss
of hearing in both the click and frequency selective tone burst
stimulations. Rasagiline treatments (0.5 and 6 mg/kg, s.c., once daily)
were started 14 h after the ﬁrst dose of kanamycin and lasted till the
second threshold measurement in the 3rd week. Mice in the Control
group received physiological saline s.c. Respective data of the
Kanamycin + Rasagiline, 3 mg/kg treatment (n= 7; no click mea-
surements) were included in the ﬁgure (empty bars) to help demon-
strate the dose-dependent eﬀect of rasagiline. The inset emphasizes
this dose-dependent eﬀect at 16 kHz, which is in the highest
sensitivity frequency range of hearing in mice. Data are the
mean ± SEM; the number of experiments is given in parentheses.
A linear mixed model, followed by pairwise comparisons, was used
for the statistical analysis (see Methods; ⁄⁄p< 0.01).
Fig. 3. Rasagiline increased the electric ﬁeld stimulation-evoked release of DA in a dose-dependent manner in the mouse cochlea. Rasagiline was
added to the perfusion from the 21st min and maintained till the end of the experiment (horizontal line). S1 and S2 bars show the electrical ﬁeld
stimulations (5 Hz, 0.5 ms, 900 shocks). Rasagiline was applied in the 10–300 lM concentration range (Ras 10, Ras 30, Ras 100 and Ras 300).
The inset indicates the dose-dependent rasagiline eﬀect on the electrical stimulation-evoked fractional release (FR) of DA, which is expressed as
the FRS2/FRS1 value (ratio of the eﬀect of stimulation in the presence compared to the absence of rasagiline). Data presented are means ± SEM;
the number of experiments is given in parentheses.
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Fig. 4. Rasagiline (100 lM) did not have any eﬀect on electrical ﬁeld stimulation-evoked DA release during inhibition of VGCCs or VGSCs. A)
Blocking VGCCs (Cd2+, 100 lM) and VGSCs (TTX, 1 lM) hindered the eﬀect of electric stimulation on the fractional release (FR) of DA, and the
potentiating eﬀect of rasagiline was also lost. Drug application is indicated by the respective horizontal lines. B) Summary and statistical analysis of
the eﬀect of Cd2+ (100 lM), TTX (1 lM), rasagiline (100 lM; Ras 100) and their combined application on electrical ﬁeld stimulation-evoked DA
release (FRS2/FRS1). The asterisks indicate that all treatment resulted in a signiﬁcant eﬀect compared to the Control. Rasagiline lost its potentiating
eﬀect in the presence of VGCC and VGSC inhibition (n.s., not signiﬁcant). Data are presented as means ± SEM. The number of experiments was
6–6 in each treatment groups, except for in the Control (n= 20). ANOVA followed by Tukey’s multiple comparisons; ⁄⁄⁄p< 0.001.
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482 and GDNF, while it downregulates the pro-apoptotic Bad
483 and Bax proteins (Bar-Am et al., 2005; Weinreb et al.,
484 2005; Youdim et al., 2006). It also increases antioxidant
485 enzyme (glutathione peroxidase and catalase) activities
486 (Kitani et al., 2000) and inhibits mPTP opening,
487 mitochondrial swelling and cytochrome c release
488 (Youdim et al., n.d.; Maruyama et al., 2001; Akao et al.,
489 2002) and caspase 3 activation (Bar-Am et al., 2005). A
490 decrease in the synaptic density of NMDA- and AMPA
491 receptors, responsible for initiating excitotoxicity, has
492 also been reported with rasagiline treatment (Gardoni
493 et al., 2011). These cellular mechanisms are considered
494 responsible for the positive in vivo eﬀects of rasagiline. In
495 addition, rasagiline has provided protection in closed
496 head injury (Huang et al., 1999) and in experimental
497 focal ischemia (Speiser et al., 1999), and it was also
498 supposed to slow the progression of Parkinson’s disease
499 (Hoy and Keating, 2012). Furthermore, its
500 neuroprotective eﬀect has also been demonstrated in the
501 peripheral nervous system, i.e., in the retina (Eigeldinger-
502 Berthou et al., 2012).
503 These eﬀects of rasagiline may counteract the
504 damages that aminoglycosides cause by disturbing
505 redox homeostasis, producing ROS (Basile et al., 1996;
506 Sha and Schacht, 1999; Poirrier et al., 2010; Huth et al.,
507 2011), and by impairing the function of auditory neurons
508 via excitotoxicity (Ruel et al., 2007; Tabuchi et al., 2010)
509 and depletion of the essential neurotrophic factors
510 (Poirrier et al., 2010).
511 In addition to these well-characterized actions,
512 rasagiline also potentiates DAergic neurotransmission in
513 the brain (Weinreb et al., 2010), and DA has an
514 important role in the feedback loop providing
515 endogenous protection against SNHLs (Lendvai et al.,
516 2011). Moreover, a recent study based on screening a
517 library of FDA-approved pharmaceuticals consisting of
518 640 compounds found that DA-modulating drugs bear
519protective eﬀects against ototoxic aminoglycosides and
520cisplatin (Vlasits et al., 2012).
521Endogenous protective pathway in the cochlea –
522boosting eﬀect of rasagiline on LOC terminals to
523increase DA release
524In our in vitro experiments, we investigated the potential of
525rasagiline to enhance the release of DA from the LOC
526terminals. DA-containing LOC ﬁbers compose the
527eﬀerent part of the cochlea-brainstem short-loop
528feedback, which plays an important role in inhibiting the
529harmful overactivation of the auditory neurons (Pujol,
5301994; Ruel et al., 2007; Lendvai et al., 2011). The
531overactivation of the Glu receptors is the consequence of
532the excessive release of Glu from hair cells, occurring in
533diﬀerent types of SNHLs (Lendvai et al., 2011), and this
534excitotoxicity leads to neuronal damage, like in ischemic
535brain injury (Vizi et al., 2013). Considering the protective
536actions of cochlear DA, several target sites have
537appeared as candidates for increasing the endogenous
538DAergic protection. We have already shown that 5-HT6/7
539antagonists (Dolevicze´nyi et al., 2008), group II mGluR
540ligands (Dolevicze´nyi et al., 2005), selective NMDA
541receptor agonists (Halmos et al., 2008) and D2 DA
542receptor antagonists (Halmos et al., 2005) provide new
543possibilities for the enhancement of DA release from the
544LOC terminals in the cochlea (Lendvai et al., 2011).
545Boosting of protective LOC feedback in synchrony
546with the endogenous, action potential-evoked release of
547DA seems to be superior to simply evoking DA release
548from the terminal independently of the on-going axonal
549activity of the LOC eﬀerents or to directly activating the
550postsynaptic DA receptors by the administration of
551appropriate receptor ligands. It can be hypothesized that
552rasagiline, registered as a selective MAO-B inhibitor
553type anti-parkinsonian drug, would meet this
Fig. 5. Inhibition of DA uptake carriers by nomifensine or low temperature inhibited the rasagiline-induced potentiation of the electrical ﬁeld
stimulation-evoked DA release in the mouse cochlea. Application of nomifensine (10 lM) or cooling down the perfusion buﬀer to 17 C was started
15 min before the beginning of the measurement of DA release (i.e., in the pre-perfusion) and was maintained till the end of the experiment.
Rasagiline was administered before S2, as in all the other experiments. Asterisks show the comparisons to Nomif 10 and 17 C, respectively.
Further comparisons are indicated with the hashmarks. Data are presented as means ± SEM; n= 6 in all treatment groups. ANOVA followed by
Tukey’s multiple comparisons; ⁄p< 0.05, ⁄⁄p< 0.01, ⁄⁄⁄p< 0.001. Nomif 10, nomifensine, 10 lM; Ras 30, rasagiline, 30 lM; Ras 100, rasagiline,
100 lM.
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554 requirement by inhibiting the metabolism of DA and
555 loading up its stores (Ha´rsing and Vizi, 1984) in the
556 LOC terminals. Indeed, rasagiline enhanced the action
557 potential-evoked release of DA in the cochlea in a
558 dose-dependent manner and did not inﬂuence the
559 resting release. The relatively higher concentrations
560 needed for its action might be due to the predominantly
561 MAO-A-dependent deamination of DA in mice (Garrick
562 and Murphy, 1980; Fornai et al., 1999). At higher
563 concentration rasagiline loses its MAO-B selectivity and
564 inhibits MAO-A, as well (Youdim et al., 2006).
565 Properly functioning VGSCs and VGCCs are
566 necessary prerequisites for the classical exocytotic
567 release of neurotransmitters. The dependence of the
568 potentiating eﬀect of rasagiline on the proper functioning
569 of VGSCs and VGCCs conﬁrmed that its action was
570 connected to the on-going axonal activity of the LOC
571 eﬀerents. In contrast to indirect acting
572 sympathomimetics, such as amphetamine, which induce
573 the release of DA independently of action-potential-
574 dependent vesicular release (Fleckenstein et al., 2007).
575 In previous reports inhibition of DA reuptake by
576 rasagiline was found in the central nervous system
577 (Lamensdorf et al., 1996; Jankovic and Stacy, 2007). The
578 role of the inhibition of DA reuptake into the LOC eﬀerent
579 terminals in the action of rasagiline was supported by the
580 loss of the potentiating eﬀect of the drug during the pre-
581 inhibition of DA uptake by the selective DA uptake
582 inhibitor nomifensine and by a low temperature.
583 Rasagiline did not enhance the resting release, being
584 in line with the therapeutic aim of boosting the action
585 potential based LOC feedback response without causing
586 a continuous and endogenous protection independent
587 elevation of DA level. Continuously enhanced level of DA
588 could also be resulted in desensitization of DA receptors
589 attenuating the protective eﬀect of the ﬁring LOC terminals.
590 The question arises regarding how the doses used
591 in vivo relate to the concentrations used in vitro and
592 whether the otoprotective concentration of rasagiline
593 could be reached in humans. A simpliﬁed calculation,
594 presuming 60% water content of body mass and perfect
595 absorption of rasagiline and its distribution in body water
596 suggested that the in vivo doses and the in vitro
597 concentrations we used were approximately the same
598 order of magnitude. Considering the general experience
599 that the eﬀective human doses are usually lower by an
600 order of magnitude than those used in mice and that
601 rasagiline is very well tolerated, its use in SNHLs is a
602 reliable possibility. The preferentially MAO-B-dependent
603 deamination of DA in human, contrary to the mouse,
604 where MAO-A is predominant (Garrick and Murphy,
605 1980; Fornai et al., 1999), might further support the
606 feasibility of a lower dose of the MAO-B inhibitor
607 rasagiline for otoprotection in human.
608 An otoprotective therapy might be delivered in the
609 form of prevention, intervention or regeneration.
610 Theoretically, the preventive therapy holds the highest
611 chance of curative action. In our case administration of
612 rasagiline started 14 h after the ﬁrst injection of
613 kanamycin and still it attenuated the threshold shift
614 signiﬁcantly in 6 mg/kg dose.
615Direct translation of our results to clinical application
616would suggest the use of rasagiline in prevention or
617intervention of acute trauma caused by an
618aminoglycoside antibiotic. However, the spectrum of
619possible therapeutical indications is wider, because of
620the strong similarities in the patomechamism of the
621diﬀerent SNHLs (Hawkins, 1973; Poirrier et al., 2010;
622Mukherjea et al., 2011). Oxidative stress and the
623consequent elevation in ROS level is a key factor in
624presbycusis (Yamasoba et al., 2013), platinum-based
625anticancer drugs- (Kopke et al., 1997; Schacht et al.,
6262012) and noise exposure-induced HLs (Henderson
627et al., 2006), as well. Degeneration of the auditory
628nerves is also playing an important role in all of these
629SNHLs (Ylikoski et al., 1974; van Ruijven et al., 2005;
630Makary et al., 2011; Maison et al., 2013; Yamasoba
631et al., 2013). Therefore rasagiline, having antioxidant,
632neuroprotective and antiapoptotic eﬀect, is predisposed
633for being also a promising choice of therapeutic tool for
634treating SNHLs other than the aminoglycoside induced
635one. In case of antitumor therapy by cisplatin and
636related compounds the concomitant administration of
637rasagiline to prevent or attenuate the side eﬀects,
638similarly to its acute use in aminoglycoside therapy,
639might be a feasible way of application. On the other
640hand, chronic treatment with rasagiline seems to be the
641reasonable therapy in presbycusis and persistent,
642moderate-level noise exposure induced HLs.
643The complex pathomechanism of SNHLs, structured
644rather like a network than like a linear cascade, together
645with the failure to ﬁnd the breakthrough in therapy till
646now, suggests that single-target interventions hold less
647promise in the therapy of SNHLs. Based on the
648signiﬁcant overlaps in the pathomechanism of SNHLs,
649rasagiline, with its multi-target action, might be eﬀective
650in treating not only the aminoglycoside-induced HL but
651other forms of SNHLs as well. Its good tolerability,
652proven since its introduction to human therapy in 2006,
653also supports the applicability of this new therapeutic
654indication.
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